Delaware Judge Denies Cordis Motion In Patent Fight With Boston Scientific
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Cordis plans to appeal a Delaware court's denial of its motion for new trials in two drug-eluting stent patent disputes with Boston Scientific
You may also be interested in...
Panel Deems Drug-Eluting Stents Safe For On-Label Use, But Wants More Data
FDA advisory panel members decided Dec. 7 that the benefit of drug-eluting stent use in FDA-approved indications outweighs the risks. But the panel expressed some skepticism about the strength of data measuring the long-term incidence of blood clots
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.